Bloomberg Law
July 16, 2021, 3:54 PM

Pfizer Vaccine Granted Priority Review for Full U.S. Approval

Timothy Annett
Timothy Annett
Bloomberg News

Pfizer Inc. said its Covid-19 vaccine was granted priority review by U.S. regulators, putting it on track for a potential full approval by early next year.

The drugmaker and its German partner BioNTech SE said in a statement Friday that the Food and Drug Administration plans to decide whether to approve the shot for use in people 16 and older by January 2022.

Shares of Pfizer gained 0.2% at 11:41 a.m. in New York trading, while BioNTech’s U.S. stock climbed 3.7%.

Pfizer’s vaccine has been administered to more Americans than any other shot so far in the U.S. immunization campaign. ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.